Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Yap, Jennifer K Litton
Purpose: We tested the ability of [18F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib.
Methods: Seven patients with germline BRCA1/2 pathogenic variants underwent [18F]FTT PET-computed tomography scanning at baseline, and five underwent repeat scanning 14 days after talazoparib initiation. Maximum uptake on PET was quantified in the primary tumor, involved nodes, contralateral pectoralis muscle, and lumbar vertebra body level 3, and compared between the two time points.
Results: Blocking of [18F]FTT was observed on the second scan. Potentially strong but nonsignificant correlations were found between changes in tumor volume (on ultrasound at 1 month v baseline) and percentage changes in tumor-to-muscle uptake ratio at 14 days from baseline (Spearman rank correlation coefficient r = 1; P = .083); and between the highest-grade hematologic toxicity and baseline bone marrow-to-muscle (B/M) uptake ratio (r = 0.72; P = .068) and percentage change in B/M ratio at 14 days from baseline (r = 0.87; P = .058).
Conclusion: We conclude that [18F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [18F]FTT uptake can predict response to PARPi and whether uptake of [18F]FTT in bone marrow may be an early predictor of hematologic toxicity.
{"title":"Pharmacodynamic Activity of [<sup>18</sup>F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With <i>BRCA1/2</i>-Mutated Breast Cancer Receiving Talazoparib.","authors":"Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Yap, Jennifer K Litton","doi":"10.1200/PO.24.00303","DOIUrl":"10.1200/PO.24.00303","url":null,"abstract":"<p><strong>Purpose: </strong>We tested the ability of [<sup>18</sup>F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib.</p><p><strong>Methods: </strong>Seven patients with germline <i>BRCA1/2</i> pathogenic variants underwent [<sup>18</sup>F]FTT PET-computed tomography scanning at baseline, and five underwent repeat scanning 14 days after talazoparib initiation. Maximum uptake on PET was quantified in the primary tumor, involved nodes, contralateral pectoralis muscle, and lumbar vertebra body level 3, and compared between the two time points.</p><p><strong>Results: </strong>Blocking of [<sup>18</sup>F]FTT was observed on the second scan. Potentially strong but nonsignificant correlations were found between changes in tumor volume (on ultrasound at 1 month <i>v</i> baseline) and percentage changes in tumor-to-muscle uptake ratio at 14 days from baseline (Spearman rank correlation coefficient <i>r</i> = 1; <i>P</i> = .083); and between the highest-grade hematologic toxicity and baseline bone marrow-to-muscle (B/M) uptake ratio (<i>r</i> = 0.72; <i>P</i> = .068) and percentage change in B/M ratio at 14 days from baseline (<i>r</i> = 0.87; <i>P</i> = .058).</p><p><strong>Conclusion: </strong>We conclude that [<sup>18</sup>F]FTT can image target engagement by PARPi, but larger studies are needed to determine whether [<sup>18</sup>F]FTT uptake can predict response to PARPi and whether uptake of [<sup>18</sup>F]FTT in bone marrow may be an early predictor of hematologic toxicity.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samantha Pollard, Morgan Ehman, Anna Hermansen, Deirdre Weymann, Emanuel Krebs, Cheryl Ho, Howard J Lim, Steven Jones, Yvonne Bombard, Timothy P Hanna, Chiquita Hessels, Holly Longstaff, Robert Cook-Deegan, Tania Bubela, Dean A Regier
Purpose: In Canada, health data are siloed, slowing bioinnovation and evidence generation for personalized cancer care. Secured data-sharing platforms (SDSPs) can enable data analysis across silos through rapid concatenation across trial and real-world settings and timely researcher access. To motivate patient participation and trust in research, it is critical to ensure that SDSP design and oversight align with patients' values and address their concerns. We sought to qualitatively characterize patient preferences for the design of a pan-Canadian SDSP.
Methods: Between January 2022 and July 2023, we conducted pan-Canadian virtual focus groups with individuals who had a personal history of cancer. Following each focus group, participants were invited to provide feedback on early-phase analysis results via a member-checking survey. Three trained qualitative researchers analyzed data using thematic analysis.
Results: Twenty-eight individuals participated across five focus groups. Four focus groups were conducted in English and one in French. Thematic analysis generated two major and five minor themes. Analytic themes spanned personal and population implications of data sharing and willingness to manage perceived risks. Participants were supportive of increasing access to health data for precision oncology research, while voicing concerns about unintended data use, reidentification, and inequitable access to costly therapeutics. To mitigate perceived risks, participants highlighted the value of data access oversight and governance and informational transparency.
Conclusion: Strategies for secured data sharing should anticipate and mitigate the risks that patients perceive. Participants supported enhancing timely research capability while ensuring safeguards to protect patient autonomy and privacy. Our study informs the development of data-governance and data-sharing frameworks that integrate real-world and trial data, informed by evidence from direct patient input.
{"title":"\"I Just Assumed This Was Already Being Done\": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology.","authors":"Samantha Pollard, Morgan Ehman, Anna Hermansen, Deirdre Weymann, Emanuel Krebs, Cheryl Ho, Howard J Lim, Steven Jones, Yvonne Bombard, Timothy P Hanna, Chiquita Hessels, Holly Longstaff, Robert Cook-Deegan, Tania Bubela, Dean A Regier","doi":"10.1200/PO.24.00184","DOIUrl":"10.1200/PO.24.00184","url":null,"abstract":"<p><strong>Purpose: </strong>In Canada, health data are siloed, slowing bioinnovation and evidence generation for personalized cancer care. Secured data-sharing platforms (SDSPs) can enable data analysis across silos through rapid concatenation across trial and real-world settings and timely researcher access. To motivate patient participation and trust in research, it is critical to ensure that SDSP design and oversight align with patients' values and address their concerns. We sought to qualitatively characterize patient preferences for the design of a pan-Canadian SDSP.</p><p><strong>Methods: </strong>Between January 2022 and July 2023, we conducted pan-Canadian virtual focus groups with individuals who had a personal history of cancer. Following each focus group, participants were invited to provide feedback on early-phase analysis results via a member-checking survey. Three trained qualitative researchers analyzed data using thematic analysis.</p><p><strong>Results: </strong>Twenty-eight individuals participated across five focus groups. Four focus groups were conducted in English and one in French. Thematic analysis generated two major and five minor themes. Analytic themes spanned personal and population implications of data sharing and willingness to manage perceived risks. Participants were supportive of increasing access to health data for precision oncology research, while voicing concerns about unintended data use, reidentification, and inequitable access to costly therapeutics. To mitigate perceived risks, participants highlighted the value of data access oversight and governance and informational transparency.</p><p><strong>Conclusion: </strong>Strategies for secured data sharing should anticipate and mitigate the risks that patients perceive. Participants supported enhancing timely research capability while ensuring safeguards to protect patient autonomy and privacy. Our study informs the development of data-governance and data-sharing frameworks that integrate real-world and trial data, informed by evidence from direct patient input.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Deepak Kilari, Michael Pierro, Bicky Thapa, Abhishek Tripathi, George Mo, Matthew Labriola, Joseph J Park, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Tanya Dorff, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Michael T Schweizer
Purpose: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy.
Methods: Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with BRCA1/2 mutations (cohort A) and those with HRR mutations without direct BRCA complex interaction (cohort B: ATM, CDK12, CHEK1, CHEK2, and FANCL). Outcomes in patients with HRR mutations with direct BRCA complex interaction were also explored (cohort C: RAD51B/C/D, RAD54L2, BARD1, GEN1, PALB2, FANCA, and BRIP1).
Results: One hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%), P < .001. Median clinical/radiographic progression-free survival (crPFS) with PARPi in cohort A was significantly longer than in cohort B: 15.9 versus 8.7 months, P = .005. PSA50 response rate to platinum therapy was higher in cohort A (62%) than in cohort B (32%), P = .024, although crPFS was not significantly different. PSA50 response rate to PARPi and platinum was 40% and 32%, respectively, in cohort C. In multivariable analysis, cohort A had significantly improved overall survival and crPFS compared with cohort B with PARPi but not platinum chemotherapy.
Conclusion: Patients with BRCA1/2-mutated PC had significantly improved outcomes to PARPi but not platinum chemotherapy compared with those with HRR mutations without direct BRCA complex interaction.
{"title":"DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.","authors":"Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Deepak Kilari, Michael Pierro, Bicky Thapa, Abhishek Tripathi, George Mo, Matthew Labriola, Joseph J Park, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Tanya Dorff, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Michael T Schweizer","doi":"10.1200/PO.24.00014","DOIUrl":"10.1200/PO.24.00014","url":null,"abstract":"<p><strong>Purpose: </strong>Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-<i>BRCA1/2</i> homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy.</p><p><strong>Methods: </strong>Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with <i>BRCA1</i>/<i>2</i> mutations (cohort A) and those with HRR mutations without direct BRCA complex interaction (cohort B: <i>ATM</i>, <i>CDK12</i>, <i>CHEK1</i>, <i>CHEK2</i>, and <i>FANCL</i>). Outcomes in patients with HRR mutations with direct BRCA complex interaction were also explored (cohort C: <i>RAD51B/C/D</i>, <i>RAD54L2</i>, <i>BARD1</i>, <i>GEN1</i>, <i>PALB2</i>, <i>FANCA</i>, and <i>BRIP1</i>).</p><p><strong>Results: </strong>One hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%), <i>P</i> < .001. Median clinical/radiographic progression-free survival (crPFS) with PARPi in cohort A was significantly longer than in cohort B: 15.9 versus 8.7 months, <i>P</i> = .005. PSA50 response rate to platinum therapy was higher in cohort A (62%) than in cohort B (32%), <i>P</i> = .024, although crPFS was not significantly different. PSA50 response rate to PARPi and platinum was 40% and 32%, respectively, in cohort C. In multivariable analysis, cohort A had significantly improved overall survival and crPFS compared with cohort B with PARPi but not platinum chemotherapy.</p><p><strong>Conclusion: </strong>Patients with <i>BRCA1/2</i>-mutated PC had significantly improved outcomes to PARPi but not platinum chemotherapy compared with those with HRR mutations without direct BRCA complex interaction.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142043913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Erratum: Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.","authors":"","doi":"10.1200/PO-24-00427","DOIUrl":"https://doi.org/10.1200/PO-24-00427","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Scott Schuetze, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Carmen J Calfa, Laura Catherine Farrington, Michael B Livingston, Kristopher Wentzel, Deepti Behl, Yelena Kier, Alissa S Marr, Margaret von Mehren, Joshua Z Press, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, Richard L Schilsky
Purpose: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (CDK4) amplification treated with palbociclib are reported.
Methods: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.
Results: Forty-two patients with CDK4 amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported.
Conclusion: Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification.
{"title":"Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.","authors":"Scott Schuetze, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Carmen J Calfa, Laura Catherine Farrington, Michael B Livingston, Kristopher Wentzel, Deepti Behl, Yelena Kier, Alissa S Marr, Margaret von Mehren, Joshua Z Press, Ramya Thota, Gina N Grantham, Abigail Gregory, Dominique C Hinshaw, Susan Halabi, Richard L Schilsky","doi":"10.1200/PO.24.00219","DOIUrl":"10.1200/PO.24.00219","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (<i>CDK4</i>) amplification treated with palbociclib are reported.</p><p><strong>Methods: </strong>Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety.</p><p><strong>Results: </strong>Forty-two patients with <i>CDK4</i> amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported.</p><p><strong>Conclusion: </strong>Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and <i>CDK4</i> amplification.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography: Aggressive or Indolent?","authors":"Peter D Zang, Salvador Jaime-Casas, Wesley Yip","doi":"10.1200/PO-24-00377","DOIUrl":"10.1200/PO-24-00377","url":null,"abstract":"","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.
奥希替尼可使表皮生长因子受体 V834L 和 L858R 组合型 NSCLC 患者获得临床获益。
{"title":"<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.","authors":"Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon","doi":"10.1200/PO.23.00215","DOIUrl":"10.1200/PO.23.00215","url":null,"abstract":"<p><p>Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, Dionna Gamble, Daniel R Crooks, Ye Yang, Lindsay Friedman, Antoun Toubaji, Pavlos Msaouel, Jonathan M Hernandez, W Marston Linehan, Mark W Ball
Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma.
对一例罕见的转移性肾肿瘤细胞瘤进行全面的分子鉴定和有效治疗。
{"title":"Molecular Characterization of Metastatic Oncocytoma With Exceptional Response to Treatment: A Case Report.","authors":"Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, Dionna Gamble, Daniel R Crooks, Ye Yang, Lindsay Friedman, Antoun Toubaji, Pavlos Msaouel, Jonathan M Hernandez, W Marston Linehan, Mark W Ball","doi":"10.1200/PO.24.00188","DOIUrl":"10.1200/PO.24.00188","url":null,"abstract":"<p><p>Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel I Nathan, Tehilla Brander, Julie Gold, Deborah Paul, Paula Klein, Kit Cheng, Johnson M Liu, Bridget K Marcellino
Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.
使用 NCCN 指南区分 TP53 CH 和镶嵌型 LFS 的益处和局限性。
{"title":"Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.","authors":"Daniel I Nathan, Tehilla Brander, Julie Gold, Deborah Paul, Paula Klein, Kit Cheng, Johnson M Liu, Bridget K Marcellino","doi":"10.1200/PO.24.00006","DOIUrl":"10.1200/PO.24.00006","url":null,"abstract":"<p><p>Benefits and limitations in using NCCN guidelines to distinguish TP53 CH from mosaic LFS.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports.","authors":"Lodovica Zullo, Elora Castanet, Zineb Maaradji, Maria Rosa Ghigna, Benjamin Bonhomme, Melissa Alamé, Benjamin Besse, Sophie Cousin, Mihaela Aldea","doi":"10.1200/PO.24.00257","DOIUrl":"https://doi.org/10.1200/PO.24.00257","url":null,"abstract":"<p><p>We report the first two cases of EGFR exon20ins SCLC, treated with amivantamab and TKIs.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}